Featured Research

Treatment for Advanced or Recurrent Endometrial Cancer

Clinicaltrials.gov identifier:
NCT05173987

Treatment
Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

Denosumab for breast cancer risk reduction in women with an inherited BRCA1 mutation (The Breast Cancer Prevention Study)

Clinicaltrials.gov identifier:
NCT04711109

Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04486352

Treatment
This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent endometrial cancer.

Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer

Clinicaltrials.gov identifier:
NCT05328908

Treatment
Comparing three drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer

Self -Perception and Intimacy After the Cancer Experience (SPICE)

Surveys, Registries, Interviews
Survey for cancer survivors ages 18-25 years old about sexual self-concept, sexual health knowledge, relationships and body image.

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

Clinicaltrials.gov identifier:
NCT05169437

Treatment
Any advanced or metastatic solid tumor except ovarian or prostate

Men at High Genetic Risk for Prostate Cancer

Clinicaltrials.gov identifier:
NCT03805919

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

Metastatic Castration Resistant Prostate Cancer Clinical Trial

Clinicaltrials.gov identifier:
NCT03460977

Treatment
This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.

Investigating the Use of Self-Acupressure for Fatigue in Ovarian Cancer Survivors

Clinicaltrials.gov identifier:
NCT03763838

Quality of Life
University of Michigan researchers are investigating the use of self-acupressure for fatigue in ovarian cancer survivors.

Women's Sexuality After Gynecological Cancer Treatments

Surveys, Registries, Interviews
Virtual or in-person interview to share personal experiences of sexuality after gynecological cancer treatment(s).

Survey for Women at High Risk for Breast Cancer on Knowledge and Perspectives about Breast Cancer Risk Factors and Screening

Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Clinicaltrials.gov identifier:
NCT04030559

Treatment
High-risk localized prostate cancer

Paid Research Interview Opportunity: Patients Receiving Neoadjuvant or First-Line Treatment for Ovarian Cancer

Surveys, Registries, Interviews
Interview for people with stage III or IV ovarian cancer

Testing a Targeted Therapy in Combination with Chemotherapy for Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT04491942

Treatment
Treatment study for people with advanced cancers

Perceptions of an Online Platform to Facilitate Sharing of Family Health History

Surveys, Registries, Interviews
Online survey for people with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53 inherited mutation or Lynch syndrome.

Preferences Survey for Women With an Inherited BRCA Mutation and Without a Cancer Diagnosis

Surveys, Registries, Interviews
Online survey for women with a BRCA1 or BRCA2 inherited mutation and no personal history of cancer.

Project MTFM: Medical Tattooing Following Mastectomy

Surveys, Registries, Interviews
Survey for breast cancer survivors following mastectomy

Testing an Immunotherapy in Patients with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT02628067

Treatment
Treatment study for people with advanced cancers

Opening the Conversation

Clinicaltrials.gov identifier:
NCT04806724

Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners

A New Risk Measurement Tool for Those at High Risk for Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04487405

Prevention
This study is using a new type of genetic test to measure ovarian cancer risk

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

Clinicaltrials.gov identifier:
NCT04550494

Treatment
Treatment study for people with advanced solid tumors

Immunotherapy and PARP Inhibitor for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with a BRCA Mutation

Clinicaltrials.gov identifier:
NCT04673448

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer

Clinicaltrials.gov identifier:
NCT04895722

Treatment
Stage 4 colorectal cancer

Pancreatic Cancer Early Detection for People at High Risk

Clinicaltrials.gov identifier:
NCT04970056

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer

Pancreatic Cancer Screening Study(CAPS5)

Clinicaltrials.gov identifier:
NCT02000089

Prevention
Screening study for people at high risk for pancreatic cancer

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

Clinicaltrials.gov identifier:
NCT03462342

Treatment
Recurrent ovarian cancer

Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer

Clinicaltrials.gov identifier:
NCT04837820

Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer

Restoring Sensation after DIEP Flap Reconstruction

Clinicaltrials.gov identifier:
NCT04533373

Prevention
Study for people undergoing DIEP flap reconstruction

Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors

Clinicaltrials.gov identifier:
NCT05505045

Quality of Life
Telehealth study for breast cancer survivors with memory issues

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Colorectal Cancer Survivors

Clinicaltrials.gov identifier:
NCT05056077

Quality of Life
Nonmetastatic colon or rectal cancer

Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

Clinicaltrials.gov identifier:
NCT05129605

Prevention
People at high risk for prostate cancer due to an inherited mutation

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05252390

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

Opening the Conversation Study

Clinicaltrials.gov identifier:
NCT04806724

Quality of Life
Videoconference sessions that address cancer related concerns for couples

Studying the Medication Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

Clinicaltrials.gov identifier:
NCT03317392

Treatment
People with castration-resistant prostate cancer with bone spread

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

Clinicaltrials.gov identifier:
NCT04455750

Treatment
Treatment study for men with metastatic prostate cancer

Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer

Clinicaltrials.gov identifier:
NCT04621721

Quality of Life
Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy

Studying Types of Therapy for Coping With Fear of Recurrence Among Breast Cancer Survivors

Clinicaltrials.gov identifier:
NCT05364450

Quality of Life
People with stage 1-3 breast cancer who completed treatment within 5 years of enrollment

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

Clinicaltrials.gov identifier:
NCT04038502

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women

Clinicaltrials.gov identifier:
NCT05287451

Prevention
Prevention study for women at high risk for ovarian cancer

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

Clinicaltrials.gov identifier:
NCT04497844

Treatment
Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

Exploring the Fertility Preservation Needs of Individuals with Positive Genetic Test Results

Surveys, Registries, Interviews
Survey and video interview for people who tested positive for an inherited mutation

Factors Influencing Reproductive Decision-Making in Individuals with a BRCA1 or BRCA2 Gene Mutation

Surveys, Registries, Interviews
Survey for people with a BRCA1 or BRCA2 mutation

Bazedoxifene Plus Conjugated Estrogens for Hot-Flashes in Women at High Risk for Breast Cancer

Clinicaltrials.gov identifier:
NCT04821141

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot-flashes

Research Opportunity for Previvors and their Romantic Partners

Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors

Clinicaltrials.gov identifier:
NCT04906200

Quality of Life
Women diagnosed with breast cancer between the ages of 15-39

BRCA 1 and 2: Interviews on Genetic Testing and Individual Experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

Clinicaltrials.gov identifier:
NCT04150042

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

Metastatic Pancreatic Cancer in US

Surveys, Registries, Interviews
People with metastatic pancreatic cancer and their caregivers

Interviews for people with a genetic test result that was later reclassified

Surveys, Registries, Interviews
People with a genetic test result that was later reclassified

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer (AVPC)

Clinicaltrials.gov identifier:
NCT04592237

Treatment
Treatment in people with aggressive metastatic prostate cancer

All of Us Research Program

Surveys, Registries, Interviews
Anyone age 18 or over

Studying Crowdfunding for Cancer

Surveys, Registries, Interviews
Cancer survivors who have used crowdfunding to help cover cancer-related costs

Treating Early-Stage Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04584255

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

Clinicaltrials.gov identifier:
NCT04194554

Treatment
Newly diagnosed prostate cancer grade group 3-5

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

Clinicaltrials.gov identifier:
NCT04644068

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

Clinicaltrials.gov identifier:
NCT04497116

Treatment
Advanced solid tumors

Screening for Cancer DNA in the Blood after Treatment for Early-Stage TNBC and/or a BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)

Clinicaltrials.gov identifier:
NCT04915755

Treatment
Early-stage TNBC or early-stage breast cancer with a BRCA mutation

ATR Inhibitor Plus Niraparib Study in Advanced Solid Tumors and Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04267939

Treatment
Advanced ovarian cancer or other solid tumors

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

Clinicaltrials.gov identifier:
NCT03231891

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

Clinicaltrials.gov identifier:
NCT04548752

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04991480

Treatment
Advanced solid tumors

Retifanlimab Alone or with Other Agents for Advanced Endometrial Cancer that Progressed with Platinum

Clinicaltrials.gov identifier:
NCT04463771

Treatment
Advanced endometrial cancer

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04367675

Prevention
People with a BRCA1 or BRCA2 mutation

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

Clinicaltrials.gov identifier:
NCT04657068

Treatment
Advanced solid tumors

CYH33 in Combination With Olaparib in Patients With Advanced Solid Tumors and DNA Damage Repair Mutations

Clinicaltrials.gov identifier:
NCT04586335

Treatment
Advanced solid tumors

Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Clinicaltrials.gov identifier:
NCT03607890

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

Clinicaltrials.gov identifier:
NCT04379999

Prevention

Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

Clinicaltrials.gov identifier:
NCT03685331

Treatment

Fear of Recurrence, Adversity, and Pain

Surveys, Registries, Interviews

Blood Markers of Early Pancreas Cancer

Clinicaltrials.gov identifier:
NCT03568630

Prevention
Screening for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk.

Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab

Clinicaltrials.gov identifier:
NCT04493060

Treatment

AMPLIFY: a new online weight loss study specifically for cancer survivors!

Clinicaltrials.gov identifier:
NCT04000880

Quality of Life

Developing a Test for the Detection of Ovarian Cancer

Clinicaltrials.gov identifier:
NCT04794322

Prevention

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Clinicaltrials.gov identifier:
NCT04995198

Surveys, Registries, Interviews

Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)

Clinicaltrials.gov identifier:
NCT02997228

Treatment

Screening for Pancreatic Cancer in Patients with an Inherited BRCA1, BRCA2, PALB2 or ATM Mutation

Clinicaltrials.gov identifier:
NCT02478892

Prevention

Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation

Clinicaltrials.gov identifier:
NCT04858334

Treatment

Research Study to Help Improve Family Communication About Inherited BRCA1 or BRCA2 Mutations

Prevention

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Clinicaltrials.gov identifier:
NCT04042831

Treatment

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)

Clinicaltrials.gov identifier:
NCT04008030

Treatment
People with metastatic colorectal cancer that is MSI-High

Pembrolizumab and Olaparib for Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

Clinicaltrials.gov identifier:
NCT04666740

Treatment

Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

Clinicaltrials.gov identifier:
NCT03581357

Quality of Life

Mobile Mindfulness Meditation Intervention for Cancer Survivors

Clinicaltrials.gov identifier:
NCT03581357

Quality of Life

A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

Surveys, Registries, Interviews

Blood Tests to Measure Ovarian Reserves in Women with a BRCA Mutation or Women Treated for Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT0823654

Olaparib Expanded - Treating Metastatic Breast Cancer in People without gBRCA Mutations

Clinicaltrials.gov identifier:
NCT03344965

Treatment

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

Surveys, Registries, Interviews

Diagnosis of Breast Cancer in Young Women - Share Your Story

Surveys, Registries, Interviews

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

Clinicaltrials.gov identifier:
NCT03990896

Treatment

A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients (E-Reach)

Clinicaltrials.gov identifier:
NCT04353973

Treatment

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

Clinicaltrials.gov identifier:
NCT02912559

Treatment

Genetic Testing for Men with Metastatic Prostate Cancer (GENTleMEN Study)

Clinicaltrials.gov identifier:
NCT03503097

Treatment

Metastatic Prostate Cancer Project

Surveys, Registries, Interviews

The Metastatic Breast Cancer Project

Surveys, Registries, Interviews

Pancreatic Cancer Screening Study for High Risk People

Clinicaltrials.gov identifier:
NCT03250078

Prevention

Denosumab and Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

Clinicaltrials.gov identifier:
NCT04067726

Prevention

Connect My Variant

Surveys, Registries, Interviews

Study for People with Unexpected Genetic Results

Clinicaltrials.gov identifier:
NCT02595957

Prevention

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job

Clinicaltrials.gov identifier:
NCT03572374

Quality of Life

Breast Cancer Treatment in Women with PALB2 Mutations

Surveys, Registries, Interviews

ELLIE's Project

Quality of Life

INTERVAL: INTense Exercise foR surVivAL in Men With Metastatic Prostate Cancer

Clinicaltrials.gov identifier:
NCT02730338

Quality of Life

RADCOMP: A Study at the Heart of Breast Cancer Treatment

Clinicaltrials.gov identifier:
NCT02603341

Treatment

Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

Surveys, Registries, Interviews

Pancreatic Cancer Early Detection

Clinicaltrials.gov identifier:
NCT02206360

Prevention

WISDOM Study

Clinicaltrials.gov identifier:
NCT02620852

Prevention

PROMPT

Clinicaltrials.gov identifier:
NCT02665195

Surveys, Registries, Interviews